BibTex RIS Cite

Klorokin ve Hidroksiklorokin Makülopatili İki Olgu

Year 2011, Volume: 24 Issue: 1, 68 - 72, 21.04.2015

Abstract

İki antimalarial ilaç kullanımına bağlı retinopati olgusu sunduk ve antimalarial tedavisinde tarama yöntemlerini değerlendirdik. Retina bölümümüzde takip edilen iki olgunun klinik kayıtları, fundus fotoğrafları, görme alanı, flöresan anjiografileri incelendi. İlk olguda testler yapılmış olduğu halde sonuçlarının yanlış yorumlanması, ikinci olguda ise hastaya tarama testlerinin öneminin yeterince anlatılmamış olması sebep olarak görüldü.

Anahtar Kelimeler: Klorokin, Hidroksiklorokin, Retinal toksisite

References

  • 1. Marmor FM. New American Academy of Ophtalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 2003 Jun;48(6):1764. doi: 10.1002/art.10980
  • 2. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133: 649- 656. doi: 10.1016/S0002-9394(02)01392-2
  • 3. Easterbrook M. Screening for antimalarial toxicity: current concepts. Can J Ophtalmol. 2002; 6:325- 328.
  • 4. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophtalmol. 2008; 23 :201- 209. doi: 10.1080/08820530802049962
  • 5. Rigaudière F, Ingster-Moati I, Hache JC, Leid J, Verdet R, Haymann P, Rigolet MH, Zanlonghi X, Defoort S, Le Gargasson JF: Updated ophtalmological screening and follow up management for long term antimalarial treatment. J Fr Ophtalmol 2004; 27:191- 199.
  • 6. Rüther K, Foerster J, Berndt S, et al. Chloroquine/hydroxychloroquine:variability of retinotoxic cumulative doses. Ophthalmologe 2007;104:875-879. doi: 10.1007/s00347-007- 1560-7
  • 7. Pluta JP, Rühter K. Retinal damage by (hydroxyl)chloroquine intake:published evidence for an efficient ophthalmological follow-up. Klin Monbl Augenheilkd 2009;226:891-896. Epub 2009 Nov. 13. doi 10.1055/s-0028-1109881
  • 8. Blyth C, Lane C: Hydroxychloroquine retinopathy:is screening necessary? BMJ. 1998; 316 :716– 717
  • 9. Gilbert ME, Savino PJ: Missing the bull’s eye. Surv Ophtalmol 2007; 52 :440- 442.
  • 10. Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, Srinivasan V, Wojtkowski M, Reichel E, Duker JS, Schuman JS, Fujimoto JG: High speed ultra high resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophtalmol 2007; 125: 775- 780.
  • 11. Razeghinejad MR, Torkaman F, Amini H: Blue yellow perimetry can be an early detector of hydroxychloroquine and chloroquine retinopathy. Med Hypotheses 2005; 65 :629- 630. doi: 10.1016/j.mehy.2005.04.005
  • 12. Gündüz K, Okka M, Zengin N, Okudan S, Özbayrak N,Acaroğlu Ş. Klorokin tedavisinde retina toksisitesinin araştırılması. T Klin Oftalmoloji 1995; 4: 47-51.
  • 13. Köse S, Akkın C, Ya_cı A, Ate_ H,Haznedaro_lu G. Klorokin retinopatisinin saptanması ve izlenmesinde kullanılan yöntemlerin etkinliği. MN Oftalmoloji 1993; 2: 299-301.
  • 14. Herman K, Leys A,Spileers W: Hydroxychloroquine retinal toxicity: two case reports and safety guidelines. Bull Soc Belge Ophtalmol 2002; 284: 21- 29.

-

Year 2011, Volume: 24 Issue: 1, 68 - 72, 21.04.2015

Abstract

-

References

  • 1. Marmor FM. New American Academy of Ophtalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum 2003 Jun;48(6):1764. doi: 10.1002/art.10980
  • 2. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Ophthalmol. 2002;133: 649- 656. doi: 10.1016/S0002-9394(02)01392-2
  • 3. Easterbrook M. Screening for antimalarial toxicity: current concepts. Can J Ophtalmol. 2002; 6:325- 328.
  • 4. Tehrani R, Ostrowski RA, Hariman R, Jay WM. Ocular toxicity of hydroxychloroquine. Semin Ophtalmol. 2008; 23 :201- 209. doi: 10.1080/08820530802049962
  • 5. Rigaudière F, Ingster-Moati I, Hache JC, Leid J, Verdet R, Haymann P, Rigolet MH, Zanlonghi X, Defoort S, Le Gargasson JF: Updated ophtalmological screening and follow up management for long term antimalarial treatment. J Fr Ophtalmol 2004; 27:191- 199.
  • 6. Rüther K, Foerster J, Berndt S, et al. Chloroquine/hydroxychloroquine:variability of retinotoxic cumulative doses. Ophthalmologe 2007;104:875-879. doi: 10.1007/s00347-007- 1560-7
  • 7. Pluta JP, Rühter K. Retinal damage by (hydroxyl)chloroquine intake:published evidence for an efficient ophthalmological follow-up. Klin Monbl Augenheilkd 2009;226:891-896. Epub 2009 Nov. 13. doi 10.1055/s-0028-1109881
  • 8. Blyth C, Lane C: Hydroxychloroquine retinopathy:is screening necessary? BMJ. 1998; 316 :716– 717
  • 9. Gilbert ME, Savino PJ: Missing the bull’s eye. Surv Ophtalmol 2007; 52 :440- 442.
  • 10. Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, Srinivasan V, Wojtkowski M, Reichel E, Duker JS, Schuman JS, Fujimoto JG: High speed ultra high resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophtalmol 2007; 125: 775- 780.
  • 11. Razeghinejad MR, Torkaman F, Amini H: Blue yellow perimetry can be an early detector of hydroxychloroquine and chloroquine retinopathy. Med Hypotheses 2005; 65 :629- 630. doi: 10.1016/j.mehy.2005.04.005
  • 12. Gündüz K, Okka M, Zengin N, Okudan S, Özbayrak N,Acaroğlu Ş. Klorokin tedavisinde retina toksisitesinin araştırılması. T Klin Oftalmoloji 1995; 4: 47-51.
  • 13. Köse S, Akkın C, Ya_cı A, Ate_ H,Haznedaro_lu G. Klorokin retinopatisinin saptanması ve izlenmesinde kullanılan yöntemlerin etkinliği. MN Oftalmoloji 1993; 2: 299-301.
  • 14. Herman K, Leys A,Spileers W: Hydroxychloroquine retinal toxicity: two case reports and safety guidelines. Bull Soc Belge Ophtalmol 2002; 284: 21- 29.
There are 14 citations in total.

Details

Primary Language Turkish
Journal Section Case Reports
Authors

Fulya Akman This is me

Eren Çerman This is me

Özlem Yenice

Haluk Kazokoğlu This is me

Publication Date April 21, 2015
Published in Issue Year 2011 Volume: 24 Issue: 1

Cite

APA Akman, F., Çerman, E., Yenice, Ö., Kazokoğlu, H. (2015). Klorokin ve Hidroksiklorokin Makülopatili İki Olgu. Marmara Medical Journal, 24(1), 68-72.
AMA Akman F, Çerman E, Yenice Ö, Kazokoğlu H. Klorokin ve Hidroksiklorokin Makülopatili İki Olgu. Marmara Med J. August 2015;24(1):68-72.
Chicago Akman, Fulya, Eren Çerman, Özlem Yenice, and Haluk Kazokoğlu. “Klorokin Ve Hidroksiklorokin Makülopatili İki Olgu”. Marmara Medical Journal 24, no. 1 (August 2015): 68-72.
EndNote Akman F, Çerman E, Yenice Ö, Kazokoğlu H (August 1, 2015) Klorokin ve Hidroksiklorokin Makülopatili İki Olgu. Marmara Medical Journal 24 1 68–72.
IEEE F. Akman, E. Çerman, Ö. Yenice, and H. Kazokoğlu, “Klorokin ve Hidroksiklorokin Makülopatili İki Olgu”, Marmara Med J, vol. 24, no. 1, pp. 68–72, 2015.
ISNAD Akman, Fulya et al. “Klorokin Ve Hidroksiklorokin Makülopatili İki Olgu”. Marmara Medical Journal 24/1 (August 2015), 68-72.
JAMA Akman F, Çerman E, Yenice Ö, Kazokoğlu H. Klorokin ve Hidroksiklorokin Makülopatili İki Olgu. Marmara Med J. 2015;24:68–72.
MLA Akman, Fulya et al. “Klorokin Ve Hidroksiklorokin Makülopatili İki Olgu”. Marmara Medical Journal, vol. 24, no. 1, 2015, pp. 68-72.
Vancouver Akman F, Çerman E, Yenice Ö, Kazokoğlu H. Klorokin ve Hidroksiklorokin Makülopatili İki Olgu. Marmara Med J. 2015;24(1):68-72.